Stefanie D. Krens

Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a <i>VAC14</i> Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy

Daniel L. Hertz, Kouros Owzar, Sherrie Lessans et al. · Clinical Cancer Research · 2016 · 57 citations · Full text

Medicine, Oncology, Pharmacology +17

Quantification of cobimetinib, cabozantinib, dabrafenib, niraparib, olaparib, vemurafenib, regorafenib and its metabolite regorafenib M2 in human plasma by UPLC–MS/MS

Stefanie D. Krens, Eric van der Meulen, Frank G. A. Jansman et al. · Biomedical Chromatography · 2019 · 48 citations · Full text

Pharmacy, Pharmaceutical Analysis, Pharmacology +17

Pharmacogenetics, Enzyme Probes and Therapeutic drug Monitoring as Potential Tools for Individualizing Taxane Therapy

Stefanie D. Krens, Howard L. McLeod, Daniel L. Hertz · Pharmacogenomics · 2013 · 39 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

The relationship between sunitinib exposure and both efficacy and toxicity in real‐world patients with renal cell carcinoma and gastrointestinal stromal tumour

Kim Westerdijk, Stefanie D. Krens, Winette T.A. van der Graaf et al. · British Journal of Clinical Pharmacology · 2020 · 29 citations · Full text

Medicine, Oncology, Pharmacology +16

Excessive toxicity of cabozantinib in a phase II study in patients with recurrent and/or metastatic salivary gland cancer

Wim van Boxtel, Maike J.M. Uijen, Stefanie D. Krens et al. · European Journal of Cancer · 2021 · 24 citations · Full text

Medicine, Oncology, Pharmacology +17